1
|
Khalil A, Bellesia G, Norton ME, Jacobsson B, Haeri S, Egbert M, Malone FD, Wapner RJ, Roman A, Faro R, Madankumar R, Strong N, Silver RM, Vohra N, Hyett J, Macpherson C, Prigmore B, Ahmed E, Demko Z, Ortiz JB, Souter V, Dar P. The Role of cfDNA Biomarkers and Patient Data in the Early Prediction of Preeclampsia: Artificial Intelligence Model. Am J Obstet Gynecol 2024:S0002-9378(24)00380-6. [PMID: 38432413 DOI: 10.1016/j.ajog.2024.02.299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Revised: 02/16/2024] [Accepted: 02/22/2024] [Indexed: 03/05/2024]
Abstract
OBJECTIVE Accurate individualized assessment of preeclampsia risk enables the identification of patients most likely to benefit from initiation of low-dose aspirin at 12-16 weeks' gestation when there is evidence for its effectiveness, as well as guiding appropriate pregnancy care pathways and surveillance. The primary objective of this study was to evaluate the performance of artificial neural network models for the prediction of preterm preeclampsia (<37 weeks' gestation) using patient characteristics available at the first antenatal visit and data from prenatal cell-free DNA (cfDNA) screening. Secondary outcomes were prediction of early onset preeclampsia (<34 weeks' gestation) and term preeclampsia (≥37 weeks' gestation). METHODS This secondary analysis of a prospective, multicenter, observational prenatal cfDNA screening study (SMART) included singleton pregnancies with known pregnancy outcomes. Thirteen patient characteristics that are routinely collected at the first prenatal visit and two characteristics of cfDNA, total cfDNA and fetal fraction (FF), were used to develop predictive models for early-onset (<34 weeks), preterm (<37 weeks), and term (≥37 weeks) preeclampsia. For the models, the 'reference' classifier was a shallow logistic regression (LR) model. We also explored several feedforward (non-linear) neural network (NN) architectures with one or more hidden layers and compared their performance with the LR model. We selected a simple NN model built with one hidden layer and made up of 15 units. RESULTS Of 17,520 participants included in the final analysis, 72 (0.4%) developed early onset, 251 (1.4%) preterm, and 420 (2.4%) term preeclampsia. Median gestational age at cfDNA measurement was 12.6 weeks and 2,155 (12.3%) had their cfDNA measurement at 16 weeks' gestation or greater. Preeclampsia was associated with higher total cfDNA (median 362.3 versus 339.0 copies/ml cfDNA; p<0.001) and lower FF (median 7.5% versus 9.4%; p<0.001). The expected, cross-validated area under the curve (AUC) scores for early onset, preterm, and term preeclampsia were 0.782, 0.801, and 0.712, respectively for the LR model, and 0.797, 0.800, and 0.713, respectively for the NN model. At a screen-positive rate of 15%, sensitivity for preterm preeclampsia was 58.4% (95% CI 0.569, 0.599) for the LR model and 59.3% (95% CI 0.578, 0.608) for the NN model.The contribution of both total cfDNA and FF to the prediction of term and preterm preeclampsia was negligible. For early-onset preeclampsia, removal of the total cfDNA and FF features from the NN model was associated with a 6.9% decrease in sensitivity at a 15% screen positive rate, from 54.9% (95% CI 52.9-56.9) to 48.0% (95% CI 45.0-51.0). CONCLUSION Routinely available patient characteristics and cfDNA markers can be used to predict preeclampsia with performance comparable to other patient characteristic models for the prediction of preterm preeclampsia. Both LR and NN models showed similar performance.
Collapse
Affiliation(s)
- Asma Khalil
- Department of Obstetrics and Gynaecology, St. George's University Hospital, University of London, London, England, UK.
| | | | - Mary E Norton
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, CA, USA
| | - Bo Jacobsson
- Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg Sweden; Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg Sweden
| | - Sina Haeri
- Austin Maternal-Fetal Medicine, Austin, TX, USA
| | | | - Fergal D Malone
- Department of Obstetrics and Gynecology, Rotunda Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Ronald J Wapner
- Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY, USA
| | - Ashley Roman
- Department of Obstetrics and Gynecology, New York University Grossman School of Medicine, New York, NY, USA
| | - Revital Faro
- Department of Obstetrics and Gynecology, Saint Peter's University Hospital, New Brunswick, NJ
| | - Rajeevi Madankumar
- Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY, USA
| | - Noel Strong
- Department of Obstetrics and Gynecology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Robert M Silver
- Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT, USA
| | - Nidhi Vohra
- Department of Obstetrics and Gynecology, North Shore University Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, USA
| | - Jon Hyett
- Department of Obstetrics and Gynecology, Royal Prince Alfred Hospital, Western Sydney University, Camperdown, NSW, Australia
| | - Cora Macpherson
- The Biostatistics Center, George Washington University, Rockville, MD, USA
| | | | | | | | | | | | - Pe'er Dar
- Department of Obstetrics and Gynecology and Women's Health, Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx, NY, USA
| |
Collapse
|
2
|
Martin K, Norton ME, MacPherson C, Demko Z, Egbert M, Haeri S, Malone F, Wapner RJ, Roman AS, Khalil A, Faro R, Madankumar R, Strong N, Silver R, Vohra N, Hyett J, Kao C, Hakonarson H, Jacobson B, Dar P. Impact of high-risk prenatal screening results for 22q11.2 deletion syndrome on obstetric and neonatal management: Secondary analysis from the SMART study. Prenat Diagn 2023; 43:1574-1580. [PMID: 38066724 DOI: 10.1002/pd.6483] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2023] [Revised: 11/13/2023] [Accepted: 11/21/2023] [Indexed: 12/24/2023]
Abstract
OBJECTIVE One goal of prenatal genetic screening is to optimize perinatal care and improve infant outcomes. We sought to determine whether high-risk cfDNA screening for 22q11.2 deletion syndrome (22q11.2DS) affected prenatal or neonatal management. METHODS This was a secondary analysis from the SMART study. Patients with high-risk cfDNA results for 22q11.2DS were compared with the low-risk cohort for pregnancy characteristics and obstetrical management. To assess differences in neonatal care, we compared high-risk neonates without prenatal genetic confirmation with a 1:1 matched low-risk cohort. RESULTS Of 18,020 eligible participants enrolled between 2015 and 2019, 38 (0.21%) were high-risk and 17,982 (99.79%) were low-risk for 22q11.2DS by cfDNA screening. High-risk participants had more prenatal diagnostic testing (55.3%; 21/38 vs. 2.0%; 352/17,982, p < 0.001) and fetal echocardiography (76.9%; 10/13 vs. 19.6%; 10/51, p < 0.001). High-risk newborns without prenatal diagnostic testing had higher rates of neonatal genetic testing (46.2%; 6/13 vs. 0%; 0/51, P < 0.001), echocardiography (30.8%; 4/13 vs. 4.0%; 2/50, p = 0.013), evaluation of calcium levels (46.2%; 6/13 vs. 4.1%; 2/49, P < 0.001) and lymphocyte count (53.8%; 7/13 vs. 15.7%; 8/51, p = 0.008). CONCLUSIONS High-risk screening results for 22q11.2DS were associated with higher rates of prenatal and neonatal diagnostic genetic testing and other 22q11.2DS-specific evaluations. However, these interventions were not universally performed, and >50% of high-risk infants were discharged without genetic testing, representing possible missed opportunities to improve outcomes for affected individuals.
Collapse
Affiliation(s)
| | - Mary E Norton
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, California, USA
| | - Cora MacPherson
- The Biostatistics Center, George Washington University, Washington, District of Columbia, USA
| | | | | | | | - Fergal Malone
- Department of Obstetrics and Gynecology, Rotunda Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Ronald J Wapner
- Department of Obstetrics and Gynecology, Columbia Presbyterian Medical Center, New York, New York, USA
| | - Ashley S Roman
- Department of Obstetrics and Gynecology, New York University Langone, New York, New York, USA
| | - Asma Khalil
- Department of Obstetrics and Gynecology, St. George's Hospital, University of London, London, UK
| | - Revital Faro
- Department of Obstetrics and Gynecology, St. Peter's University Hospital, New Brunswick, New Jersy, USA
| | - Rajeevi Madankumar
- Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York, USA
| | - Noel Strong
- Department of Obstetrics and Gynecology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Robert Silver
- Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, Utah, USA
| | - Nidhi Vohra
- Department of Obstetrics and Gynecology, North Shore University Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, New York, USA
| | - Jon Hyett
- Department of Obstetrics and Gynecology, Royal Prince Alfred Hospital, University of Sydney, Camperdown, New South Wales, Australia
| | - Charlly Kao
- Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
| | - Hakon Hakonarson
- Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
| | - Bo Jacobson
- Department of Obstetrics and Gynecology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Department of Obstetrics and Gynaecology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Pe'er Dar
- Department of Obstetrics and Gynecology and Women's Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA
| |
Collapse
|
3
|
Norton ME, MacPherson C, Demko Z, Egbert M, Malone F, Wapner RJ, Roman AS, Khalil A, Faro R, Madankumar R, Strong N, Haeri S, Silver R, Vohra N, Hyett J, Martin K, Rabinowitz M, Jacobsson B, Dar P. Obstetrical, perinatal, and genetic outcomes associated with nonreportable prenatal cell-free DNA screening results. Am J Obstet Gynecol 2023; 229:300.e1-300.e9. [PMID: 36965866 DOI: 10.1016/j.ajog.2023.03.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Revised: 03/20/2023] [Accepted: 03/20/2023] [Indexed: 03/27/2023]
Abstract
BACKGROUND The clinical implications of nonreportable cell-free DNA screening results are uncertain, but such results may indicate poor placental implantation in some cases and be associated with adverse obstetrical and perinatal outcomes. OBJECTIVE This study aimed to assess the outcomes of pregnancies with nonreportable cell-free DNA screening in a cohort of patients with complete genetic and obstetrical outcomes. STUDY DESIGN This was a prespecified secondary analysis of a multicenter prospective observational study of prenatal cell-free DNA screening for fetal aneuploidy and 22q11.2 deletion syndrome. Participants who underwent cell-free DNA screening from April 2015 through January 2019 were offered participation. Obstetrical outcomes and neonatal genetic testing results were collected from 21 primary-care and referral centers in the United States, Europe, and Australia. The primary outcome was risk for adverse obstetrical and perinatal outcomes (aneuploidy, preterm birth at <28, <34, and <37 weeks' gestation, preeclampsia, small for gestational age or birthweight <10th percentile for gestational week, and a composite outcome that included preterm birth at <37 weeks, preeclampsia, small for gestational age, and stillbirth at >20 weeks) after nonreportable cell-free DNA screening because of low fetal fraction or other causes. Multivariable analyses were performed, adjusting for variables known to be associated with obstetrical and perinatal outcomes, nonreportable results, or fetal fraction. RESULTS In total, 25,199 pregnant individuals were screened, and 20,194 were enrolled. Genetic confirmation was missing in 1165 (5.8%), 1085 (5.4%) were lost to follow-up, and 93 (0.5%) withdrew; the final study cohort included 17,851 (88.4%) participants who had cell-free DNA, fetal or newborn genetic confirmatory testing, and obstetrical and perinatal outcomes collected. Results were nonreportable in 602 (3.4%) participants. A sample was redrawn and testing attempted again in 427; in 112 (26.2%) participants, results were again nonreportable. Nonreportable results were associated with higher body mass index, chronic hypertension, later gestational age, lower fetal fraction, and Black race. Trisomy 13, 18, or 21 was confirmed in 1.6% with nonreportable tests vs 0.7% with reported results (P=.013). Rates of preterm birth at <28, 34, and 37 weeks, preeclampsia, and the composite outcome were higher among participants with nonreportable results, and further increased among those with a second nonreportable test, whereas the rate of small for gestational age infants was not increased. After adjustment for confounders, the adjusted odds ratios were 2.2 (95% confidence interval, 1.1-4.4) and 2.6 (95% confidence interval, 0.6-10.8) for aneuploidy, and 1.5 (95% confidence interval, 1.2-1.8) and 2.1 (95% confidence interval, 1.4-3.2) for the composite outcome after a first and second nonreportable test, respectively. Of the patients with nonreportable tests, 94.9% had a live birth, as opposed to 98.8% of those with reported test results (adjusted odds ratio for livebirth, 0.20 [95% confidence interval, 0.13-0.30]). CONCLUSION Patients with nonreportable cell-free DNA results are at increased risk for a number of adverse outcomes, including aneuploidy, preeclampsia, and preterm birth. They should be offered diagnostic genetic testing, and clinicians should be aware of the increased risk of pregnancy complications.
Collapse
Affiliation(s)
- Mary E Norton
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, CA.
| | - Cora MacPherson
- Biostatistics Center, George Washington University, Washington, DC
| | | | | | - Fergal Malone
- Department of Obstetrics and Gynaecology, Rotunda Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Ronald J Wapner
- Department of Obstetrics and Gynecology, Columbia Presbyterian Medical Center, New York, NY
| | - Ashley S Roman
- Department of Obstetrics and Gynecology, New York University Langone Health, New York, NY
| | - Asma Khalil
- Department of Obstetrics and Gynaecology, St George's Hospital, University of London, London, United Kingdom
| | - Revital Faro
- Department of Obstetrics and Gynecology, Saint Peter's University Hospital, New Brunswick, NJ
| | - Rajeevi Madankumar
- Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, Hyde Park, NY
| | - Noel Strong
- Department of Obstetrics, Gynecology, and Reproductive Science, Icahn School of Medicine at Mount Sinai, New York, NY
| | - Sina Haeri
- Austin Maternal-Fetal Medicine, Austin, TX
| | - Robert Silver
- Department of Obstetrics and Gynecology, The University of Utah, Salt Lake City, UT
| | - Nidhi Vohra
- Department of Obstetrics and Gynecology, North Shore University Hospital, Manhasset, NY
| | - Jon Hyett
- Department of Obstetrics and Gynaecology, Royal Prince Alfred Hospital and Western Sydney University, Sydney, Australia
| | | | | | - Bo Jacobsson
- Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Obstetrics and Gynecology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Pe'er Dar
- Department of Obstetrics and Gynecology and Women's Health, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY
| |
Collapse
|
4
|
Nichols AR, Haeri S, Rudine A, Burns N, Rathouz PJ, Hedderson MM, Abrams SA, Foster SF, Rickman R, McDonnold M, Widen EM. Prenatal Weight Change Trajectories and Perinatal Outcomes among Twin Gestations. Am J Perinatol 2023:10.1055/a-2091-1254. [PMID: 37164320 PMCID: PMC10782825 DOI: 10.1055/a-2091-1254] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
OBJECTIVE Despite an increase in twin pregnancies in recent decades, the Institute of Medicine twin weight gain recommendations remain provisional and provide no guidance for the pattern or timing of weight change. We sought to characterize gestational weight change trajectory patterns and examine associations with birth outcomes in a cohort of twin pregnancies. STUDY DESIGN Prenatal and delivery records were examined for 320 twin pregnancies from a maternal-fetal medicine practice in Austin, TX 2011-2019. Prenatal weights for those with >1 measured weight in the first trimester and ≥3 prenatal weights were included in analyses. Trajectories were estimated to 32 weeks (mean delivery: 33.7 ± 3.3 weeks) using flexible latent class mixed models with low-rank thin-plate splines. Associations between trajectory classes and infant outcomes were analyzed using multivariable Poisson or linear regression. RESULTS Weight change from prepregnancy to delivery was 15.4 ± 6.3 kg for people with an underweight body mass index, 15.4 ± 5.8 kg for healthy weight, 14.7 ± 6.9 kg for overweight, and 12.5 ± 6.4 kg for obesity. Three trajectory classes were identified: low (Class 1), moderate (Class 2), or high gain (Class 3). Class 1 (24.7%) maintained weight for 15 weeks and then gained an estimated 6.6 kg at 32 weeks. Class 2 (60.9%) exhibited steady gain with 13.5 kg predicted total gain, and Class 3 (14.4%) showed rapid gain across pregnancy with 21.3 kg predicted gain. Compared to Class 1, Class 3 was associated with higher birth weight z-score (β = 0.63, 95% confidence interval [CI]: 0.31,0.96), increased risk for large for gestational age (IRR = 5.60, 95% CI: 1.59, 19.67), and birth <32 weeks (IRR = 2.44, 95%CI: 1.10, 5.4) that was attenuated in sensitivity analyses. Class 2 was associated with moderately elevated birth weight z-score (β = 0.24, 95%CI: 0.00, 0.48, p = 0.050). CONCLUSION Gestational weight change followed a low, moderate, or high trajectory; both moderate and high gain patterns were associated with increased infant size outcomes. Optimal patterns of weight change that balance risk during the prenatal, perinatal, and neonatal periods require further investigation, particularly in high-risk twin pregnancies. KEY POINTS · A majority gained weight below IOM twin recommendations.. · Three patterns of GWC across pregnancy were identified.. · Moderate or high GWC was associated with infant size..
Collapse
Affiliation(s)
- Amy R Nichols
- Department of Nutritional Sciences, The University of Texas at Austin, Austin, Texas
| | - Sina Haeri
- Women's Center of Texas, St. David's Healthcare, Austin, Texas
| | - Anthony Rudine
- Office of Research, St. David's Healthcare, Austin, Texas
| | - Natalie Burns
- Department of Statistics, University of Florida, Gainesville, Florida
| | - Paul J Rathouz
- Department of Population Health and Biomedical Data Science Hub, The University of Texas at Austin Dell Medical School, Austin, Texas
| | - Monique M Hedderson
- Division of Research, Kaiser Permanente Northern California, Oakland, California
| | - Steven A Abrams
- Department of Pediatrics, The University of Texas at Austin Dell Medical School, Austin, Texas
| | - Saralyn F Foster
- Department of Nutritional Sciences, The University of Texas at Austin, Austin, Texas
| | - Rachel Rickman
- Department of Nutritional Sciences, The University of Texas at Austin, Austin, Texas
| | | | - Elizabeth M Widen
- Department of Nutritional Sciences, The University of Texas at Austin, Austin, Texas
| |
Collapse
|
5
|
Martin K, Dar P, MacPherson C, Egbert M, Demko Z, Parmar S, Hashimoto K, Haeri S, Malone F, Wapner RJ, Roman AS, Khalil A, Faro R, Madankumar R, Strong N, Silver RM, Vohra N, Hyett J, Rabinowitz M, Kao C, Hakonarson H, Jacobsson B, Norton ME. Performance of prenatal cfDNA screening for sex chromosomes. Genet Med 2023:100879. [PMID: 37154148 DOI: 10.1016/j.gim.2023.100879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2023] [Revised: 04/29/2023] [Accepted: 04/30/2023] [Indexed: 05/10/2023] Open
Abstract
PURPOSE To assess the performance of cell-free DNA (cfDNA) screening to detect sex chromosome aneuploidies (SCA) in an unselected obstetrical population with genetic confirmation. METHODS This was a planned secondary analysis of the multicenter, prospective SMART study. Patients receiving cfDNA results for autosomal aneuploidies and who had confirmatory genetic results for the relevant sex chromosomal aneuploidies were included. Screening performance for SCAs, including monosomy X (MX) and the sex chromosome trisomies (SCTs; 47,XXX; 47,XXY; 47,XYY) was determined. Fetal sex concordance between cfDNA and genetic screening was also evaluated in euploid pregnancies. RESULTS 17,538 cases met inclusion criteria. Performance of cfDNA for MX, SCTs and fetal sex was determined in 17,297, 10,333 and 14,486 pregnancies, respectively. Sensitivity, specificity, and PPV of cfDNA were 83.3%, 99.9%, and 22.7% for MX, and 70.4%, 99.9%, and 82.6% for the combined SCTs. The accuracy of fetal sex prediction by cfDNA was 100%. CONCLUSION Screening performance of cfDNA for SCAs is comparable to that reported in other studies. The PPV for the SCTs was similar to the autosomal trisomies, while the PPV for MX was substantially lower. No discordance in fetal sex was observed between cfDNA and postnatal genetic screening in euploid pregnancies. These data will assist interpretation and counseling for cfDNA results for sex chromosomes.
Collapse
Affiliation(s)
| | - Pe'er Dar
- Department of Obstetrics and Gynecology and Women's Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA
| | - Cora MacPherson
- The Biostatistics Center, George Washington University, Washington, DC, USA
| | | | | | | | | | | | - Fergal Malone
- Rotunda Hospital, Royal College of Surgeons in Ireland, Department of Obstetrics and Gynecology, Dublin, Ireland
| | - Ronald J Wapner
- Columbia Presbyterian Medical Center, Department of Obstetrics and Gynecology, New York, NY, 10032, USA
| | - Ashley S Roman
- New York University Langone, Department of Obstetrics and Gynecology, New York, NY, USA
| | - Asma Khalil
- St. George's Hospital, University of London, Department of Obstetrics and Gynecology, London, SW17 0RE, United Kingdom
| | - Revital Faro
- St. Peter's University Hospital, Department of Obstetrics and Gynecology, New Brunswick, NJ, USA
| | - Rajeevi Madankumar
- Long Island Jewish Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Obstetrics and Gynecology, New Hyde Park, NY, USA
| | - Noel Strong
- Icahn School of Medicine at Mount Sinai, Department of Obstetrics and Gynecology, New York, NY, USA
| | - Robert M Silver
- University of Utah, Department of Obstetrics and Gynecology, Salt Lake City, UT 84112, USA
| | - Nidhi Vohra
- North Shore University Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Department of Obstetrics and Gynecology, Manhasset, NY, USA
| | - Jon Hyett
- Western Sydney University, Department of Obstetrics and Gynaecology, Liverpool NSW 2170, Australia
| | | | - Charlly Kao
- Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Hakon Hakonarson
- Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Bo Jacobsson
- Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Mary E Norton
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, CA.
| |
Collapse
|
6
|
Haeri S, Norton ME, Jacobsson B, MacPherson C, Egbert M, Demko Z, Souter V, Dar P. High fetal fraction on cell-free fetal DNA screening: is it associated with adverse perinatal outcomes? Am J Obstet Gynecol 2023. [DOI: 10.1016/j.ajog.2022.11.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
7
|
Valverde VL, Althaus E, Horton L, La Rosa M, Haeri S. Economic and environmental impact of Maternal-Fetal Telemedicine (teleMFM). Am J Obstet Gynecol 2023. [DOI: 10.1016/j.ajog.2022.11.423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
8
|
Berry N, Zhang Y, Haeri S. Contact models for the Multi-Sphere Discrete Element Method. POWDER TECHNOL 2022. [DOI: 10.1016/j.powtec.2022.118209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
9
|
Costantine MM, Sibai B, Bombard AT, Sarno M, West H, Haas DM, Tita AT, Paidas MJ, Clark EA, Boggess K, Grotegut C, Grobman W, Su EJ, Burd I, Saade G, Chavez MR, Paglia MJ, Merriam A, Torres C, Habli M, Macones G, Wen T, Bofill J, Palatnik A, Edwards RK, Haeri S, Oberoi P, Mazloom A, Cooper M, Lockton S, Hankins GD. Performance of a Multianalyte 'Rule-Out' Assay in Pregnant Individuals With Suspected Preeclampsia. Hypertension 2022; 79:1515-1524. [PMID: 35545947 PMCID: PMC9172903 DOI: 10.1161/hypertensionaha.122.19038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Accepted: 04/27/2022] [Indexed: 11/16/2022]
Abstract
BACKGROUND The ability to diagnose preeclampsia clinically is suboptimal. Our objective was to validate a novel multianalyte assay and characterize its performance, when intended for use as an aid to rule-out preeclampsia. METHODS Prospective, multicenter cohort study of pregnant individuals presenting between 280/7 and 366/7 weeks' with preeclampsia-associated signs and symptoms. Individuals not diagnosed with preeclampsia after baseline evaluation were enrolled in the study cohort, with those who later developed preeclampsia, classified as cases and compared with a negative control group who did not develop preeclampsia. Individuals with assay values at time of enrollment ≥0.0325, determined using a previously developed algorithm, considered at risk. The primary analysis was the time to develop preeclampsia assessed using a multivariate Cox regression model. RESULTS One thousand thirty-six pregnant individuals were enrolled in the study cohort with an incidence of preeclampsia of 30.3% (27.6%-33.2%). The time to develop preeclampsia was shorter for those with an at-risk compared with negative assay result (log-rank P<0.0001; adjusted hazard ratio of 4.81 [3.69-6.27, P<0.0001]). The performance metrics for the assay to rule-out preeclampsia within 7 days of enrollment showed a sensitivity 76.4% (67.5%-83.5%), negative predictive value 95.0% (92.8%-96.6%), and negative likelihood ratio 0.46 (0.32-0.65). Assay performance improved if delivery occurred <37 weeks and for individuals enrolled between 28 and 35 weeks. CONCLUSIONS We confirmed that a novel multianalyte assay was associated with the time to develop preeclampsia and has a moderate sensitivity and negative likelihood ratio but high negative predictive value when assessed as an aid to rule out preeclampsia within 7 days of enrollment. REGISTRATION The study was registered on Clinicaltrials.gov (Identifier NCT02780414).
Collapse
Affiliation(s)
- Maged M. Costantine
- Departments of Obstetrics and Gynecology of The Ohio State University, Columbus (M.M.C)
| | - Baha Sibai
- The University of Texas Health Sciences Houston (B.S)
| | | | - Mark Sarno
- Vision Clinical Research, LLC, San Marcos, CA (M.S.)
| | - Holly West
- The University of Texas Medical Branch, Galveston, TX (H.W., G.D.H., G.S.)
| | | | - Alan T. Tita
- University of Alabama at Birmingham and Center for Women’s Reproductive Health (A.T.T.)
| | | | | | - Kim Boggess
- University of North Carolina, Chapel Hill (K.B.)
| | | | | | | | - Irina Burd
- Johns Hopkins University, Baltimore, MD (I.B.)
| | - George Saade
- The University of Texas Medical Branch, Galveston, TX (H.W., G.D.H., G.S.)
| | - Martin R. Chavez
- NYU Langone Hospital-Long Island, NYU Long Island School of Medicine, Mineola, NY (M.R.C.)
| | | | | | - Carlos Torres
- Regional Obstetrical Consultants P.C., Chattanooga, TN (C.T.)
| | | | - Georges Macones
- Washington University School of Medicine, St Louis, MO (G.M.)
| | - Tony Wen
- University of Mississippi, Jackson, MS (T.W., J.B.)
| | - James Bofill
- University of Mississippi, Jackson, MS (T.W., J.B.)
| | | | | | - Sina Haeri
- Austin Maternal Fetal Medicine, TX (S.H.)
| | - Pankaj Oberoi
- Progenity, Inc, San Diego, CA (P.O., A.M., M.C., S.L.)
| | - Amin Mazloom
- Progenity, Inc, San Diego, CA (P.O., A.M., M.C., S.L.)
| | | | | | - Gary D. Hankins
- The University of Texas Medical Branch, Galveston, TX (H.W., G.D.H., G.S.)
| |
Collapse
|
10
|
Martin K, Dar P, Jacobsson B, MacPherson C, Malone F, Wapner R, Roman A, Khalil A, Faro R, Madankumar R, Edwards L, Haeri S, Silver R, Vohra N, Hyett J, Clunie G, Demko Z, Rabinowitz M, Hakonarson H, Norton M. Multicentre Prospective Study of SNP-Based cfDNA Screening for Aneuploidy with Genetic Confirmation in 18 497 Pregnancies. Journal of Obstetrics and Gynaecology Canada 2022. [DOI: 10.1016/j.jogc.2022.02.068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
11
|
Dar P, Jacobsson B, MacPherson C, Egbert M, Malone F, Wapner RJ, Roman AS, Khalil A, Faro R, Madankumar R, Edwards L, Haeri S, Silver R, Vohra N, Hyett J, Clunie G, Demko Z, Martin K, Rabinowitz M, Flood K, Carlsson Y, Doulaveris G, Malone C, Hallingstrom M, Klugman S, Clifton R, Kao C, Hakonarson H, Norton ME. Cell-free DNA screening for trisomies 21, 18, and 13 in pregnancies at low and high risk for aneuploidy with genetic confirmation. Am J Obstet Gynecol 2022; 227:259.e1-259.e14. [PMID: 35085538 DOI: 10.1016/j.ajog.2022.01.019] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2021] [Revised: 01/07/2022] [Accepted: 01/11/2022] [Indexed: 11/17/2022]
Abstract
BACKGROUND Cell-free DNA noninvasive prenatal screening for trisomies 21, 18, and 13 has been rapidly adopted into clinical practice. However, previous studies are limited by a lack of follow-up genetic testing to confirm the outcomes and accurately assess test performance, particularly in women at a low risk for aneuploidy. OBJECTIVE To measure and compare the performance of cell-free DNA screening for trisomies 21, 18, and 13 between women at a low and high risk for aneuploidy in a large, prospective cohort with genetic confirmation of results STUDY DESIGN: This was a multicenter prospective observational study at 21 centers in 6 countries. Women who had single-nucleotide-polymorphism-based cell-free DNA screening for trisomies 21, 18, and 13 were enrolled. Genetic confirmation was obtained from prenatal or newborn DNA samples. The test performance and test failure (no-call) rates were assessed for the cohort, and women with low and high previous risks for aneuploidy were compared. An updated cell-free DNA algorithm blinded to the pregnancy outcome was also assessed. RESULTS A total of 20,194 women were enrolled at a median gestational age of 12.6 weeks (interquartile range, 11.6-13.9). The genetic outcomes were confirmed in 17,851 cases (88.4%): 13,043 (73.1%) low-risk and 4808 (26.9%) high-risk cases for aneuploidy. Overall, 133 trisomies were diagnosed (100 trisomy 21; 18 trisomy 18; 15 trisomy 13). The cell-free DNA screen positive rate was lower in the low-risk vs the high-risk group (0.27% vs 2.2%; P<.0001). The sensitivity and specificity were similar between the groups. The positive predictive value for the low- and high-risk groups was 85.7% vs 97.5%; P=.058 for trisomy 21; 50.0% vs 81.3%; P=.283 for trisomy 18; and 62.5% vs 83.3; P=.58 for trisomy 13, respectively. Overall, 602 (3.4%) patients had no-call result after the first draw and 287 (1.61%) after including cases with a second draw. The trisomy rate was higher in the 287 cases with no-call results than patients with a result on a first draw (2.8% vs 0.7%; P=.001). The updated algorithm showed similar sensitivity and specificity to the study algorithm with a lower no-call rate. CONCLUSION In women at a low risk for aneuploidy, single-nucleotide-polymorphism-based cell-free DNA has high sensitivity and specificity, positive predictive value of 85.7% for trisomy 21 and 74.3% for the 3 common trisomies. Patients who receive a no-call result are at an increased risk of aneuploidy and require additional investigation.
Collapse
Affiliation(s)
- Pe'er Dar
- Department of Obstetrics and Gynecology and Women's Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.
| | - Bo Jacobsson
- Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Obstetrics and Gynecology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Cora MacPherson
- The Biostatistics Center, George Washington University, Washington, DC
| | | | - Fergal Malone
- Department of Obstetrics and Gynecology, Rotunda Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Ronald J Wapner
- Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY
| | - Ashley S Roman
- Department of Obstetrics and Gynecology, New York University Grossman School of Medicine, New York, NY
| | - Asma Khalil
- Department of Obstetrics and Gynecology, St George's Hospital, University of London, London, United Kingdom
| | - Revital Faro
- Department of Obstetrics and Gynecology, St. Peter's University Hospital, New Brunswick, NJ
| | - Rajeevi Madankumar
- Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, Hyde Park, NY
| | | | - Sina Haeri
- Austin Maternal-Fetal Medicine, Austin, TX
| | - Robert Silver
- Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT
| | - Nidhi Vohra
- Department of Obstetrics and Gynecology, North Shore University Hospital, Manhasset, NY
| | - Jon Hyett
- Department of Obstetrics and Gynecology, Royal Prince Alfred Hospital, University of Sydney, Camperdown, Australia
| | - Garfield Clunie
- Department of Obstetrics and Gynecology, Icahn School of Medicine at Mount Sinai, New York, NY
| | | | | | | | - Karen Flood
- Department of Obstetrics and Gynecology, Rotunda Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Ylva Carlsson
- Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Obstetrics and Gynecology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Georgios Doulaveris
- Department of Obstetrics and Gynecology and Women's Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
| | - Ciara Malone
- Department of Obstetrics and Gynecology, Rotunda Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Maria Hallingstrom
- Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Susan Klugman
- Department of Obstetrics and Gynecology and Women's Health, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY
| | - Rebecca Clifton
- The Biostatistics Center, George Washington University, Washington, DC
| | - Charlly Kao
- Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA
| | - Hakon Hakonarson
- Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA
| | - Mary E Norton
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, CA
| |
Collapse
|
12
|
Dar P, Jacobsson B, Clifton R, Egbert M, Malone F, Wapner RJ, Roman AS, Khalil A, Faro R, Madankumar R, Edwards L, Strong N, Haeri S, Silver R, Vohra N, Hyett J, Demko Z, Martin K, Rabinowitz M, Flood K, Carlsson Y, Doulaveris G, Daly S, Hallingström M, MacPherson C, Kao C, Hakonarson H, Norton ME. Cell-free DNA screening for prenatal detection of 22q11.2 deletion syndrome. Am J Obstet Gynecol 2022; 227:79.e1-79.e11. [PMID: 35033576 DOI: 10.1016/j.ajog.2022.01.002] [Citation(s) in RCA: 27] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Revised: 01/03/2022] [Accepted: 01/05/2022] [Indexed: 11/19/2022]
Abstract
BACKGROUND Historically, prenatal screening has focused primarily on the detection of fetal aneuploidies. Cell-free DNA now enables noninvasive screening for subchromosomal copy number variants, including 22q11.2 deletion syndrome (or DiGeorge syndrome), which is the most common microdeletion and a leading cause of congenital heart defects and neurodevelopmental delay. Although smaller studies have demonstrated the feasibility of screening for 22q11.2 deletion syndrome, large cohort studies with confirmatory postnatal testing to assess test performance have not been reported. OBJECTIVE This study aimed to assess the performance of single-nucleotide polymorphism-based, prenatal cell-free DNA screening for detection of 22q11.2 deletion syndrome. STUDY DESIGN Patients who underwent single-nucleotide polymorphism-based prenatal cell-free DNA screening for 22q11.2 deletion syndrome were prospectively enrolled at 21 centers in 6 countries. Prenatal or newborn DNA samples were requested in all cases for genetic confirmation using chromosomal microarrays. The primary outcome was sensitivity, specificity, positive predictive value, and negative predictive value of cell-free DNA screening for the detection of all deletions, including the classical deletion and nested deletions that are ≥500 kb, in the 22q11.2 low-copy repeat A-D region. Secondary outcomes included the prevalence of 22q11.2 deletion syndrome and performance of an updated cell-free DNA algorithm that was evaluated with blinding to the pregnancy outcome. RESULTS Of the 20,887 women enrolled, a genetic outcome was available for 18,289 (87.6%). A total of 12 22q11.2 deletion syndrome cases were confirmed in the cohort, including 5 (41.7%) nested deletions, yielding a prevalence of 1 in 1524. In the total cohort, cell-free DNA screening identified 17,976 (98.3%) cases as low risk for 22q11.2 deletion syndrome and 38 (0.2%) cases as high risk; 275 (1.5%) cases were nonreportable. Overall, 9 of 12 cases of 22q11.2 were detected, yielding a sensitivity of 75.0% (95% confidence interval, 42.8-94.5); specificity of 99.84% (95% confidence interval, 99.77-99.89); positive predictive value of 23.7% (95% confidence interval, 11.44-40.24), and negative predictive value of 99.98% (95% confidence interval, 99.95-100). None of the cases with a nonreportable result was diagnosed with 22q11.2 deletion syndrome. The updated algorithm detected 10 of 12 cases (83.3%; 95% confidence interval, 51.6-97.9) with a lower false positive rate (0.05% vs 0.16%; P<.001) and a positive predictive value of 52.6% (10/19; 95% confidence interval, 28.9-75.6). CONCLUSION Noninvasive cell-free DNA prenatal screening for 22q11.2 deletion syndrome can detect most affected cases, including smaller nested deletions, with a low false positive rate.
Collapse
Affiliation(s)
- Pe'er Dar
- Department of Obstetrics and Gynecology and Women's Health, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY.
| | - Bo Jacobsson
- Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Obstetrics and Gynecology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - Rebecca Clifton
- The Biostatistics Center, George Washington University, Rockville, MD
| | | | - Fergal Malone
- Department of Obstetrics and Gynecology, Rotunda Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Ronald J Wapner
- Department of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY
| | - Ashley S Roman
- Department of Obstetrics and Gynecology, New York University Langone, New York, NY
| | - Asma Khalil
- Department of Obstetrics and Gynaecology, St George's Hospital, University of London, London, United Kingdom
| | - Revital Faro
- Department of Obstetrics and Gynecology, Saint Peter's University Hospital, New Brunswick, NJ
| | - Rajeevi Madankumar
- Department of Obstetrics and Gynecology, Long Island Jewish Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY
| | | | - Noel Strong
- Department of Obstetrics and Gynecology, Icahn School of Medicine at Mount Sinai, New York, NY
| | - Sina Haeri
- Austin Maternal-Fetal Medicine, Austin, TX
| | - Robert Silver
- Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT
| | - Nidhi Vohra
- Department of Obstetrics and Gynecology, North Shore University Hospital, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY
| | - Jon Hyett
- Department of Obstetrics and Gynecology, Royal Prince Alfred Hospital, University of Sydney, Camperdown, New South Wales, Australia
| | | | | | | | - Karen Flood
- Department of Obstetrics and Gynecology, Rotunda Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Ylva Carlsson
- Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Georgios Doulaveris
- Department of Obstetrics and Gynecology and Women's Health, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY
| | - Sean Daly
- Department of Obstetrics and Gynecology, Rotunda Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Maria Hallingström
- Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - Cora MacPherson
- The Biostatistics Center, George Washington University, Rockville, MD
| | - Charlly Kao
- Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA
| | - Hakon Hakonarson
- Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA
| | - Mary E Norton
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, CA
| |
Collapse
|
13
|
Dar P, MacPherson C, Jacobsson B, Egbert M, Malone FD, Wapner RJ, Roman AS, Khalil A, Faro R, Madankumar R, Edwards L, Strong N, Haeri S, Silver RM, Vohra N, Hyett J, Clifton R, Kao C, Martin K, Demko Z, Norton ME. cfDNA prenatal screening for Cri-Du-Chat, Prader-Willi/Angelman and 1p36del syndromes in 10,971 pregnancies with genetic confirmation. Am J Obstet Gynecol 2022. [DOI: 10.1016/j.ajog.2021.11.868] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
14
|
La Rosa M, Mauricio M, Lindsley W, Haeri S. Is a routine 3rd trimester ultrasound exam in low-risk pregnancies warranted? Am J Obstet Gynecol 2022. [DOI: 10.1016/j.ajog.2021.11.928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
15
|
Greiner AL, Haeri S, Davis A, Nidey N. Examining the association between preterm birth and geographic disparities in the Maternal-Fetal Medicine physician workforce. Am J Obstet Gynecol 2022. [DOI: 10.1016/j.ajog.2021.11.294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
16
|
Nidey N, Haeri S, Greiner AL. Examining geographic access to Maternal-Fetal Medicine care across the United States. Am J Obstet Gynecol 2022. [DOI: 10.1016/j.ajog.2021.11.934] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
17
|
Haeri S, Mauricio M, Lindsley W, La Rosa M. Maternal-Fetal Telemedicine: the impact of a national hub and spoke model on critical access communities. Am J Obstet Gynecol 2022. [DOI: 10.1016/j.ajog.2021.11.908] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
18
|
|
19
|
Dar P, Jacobsson B, Egbert M, Malone FD, Wapner RJ, Roman A, Khalil A, Faro R, Madankumar R, Edwards L, Strong N, Haeri S, Silver RM, Vohra N, Hyett J, Martin K, Clifton R, Kao C, Norton ME. 67 Multicenter prospective study of SNP-based cfDNA for 22q11.2 deletion in 18,289 pregnancies with genetic confirmation. Am J Obstet Gynecol 2021. [DOI: 10.1016/j.ajog.2020.12.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
20
|
Kern-Goldberger A, Haeri S, Lindsley W. 627 Examining ultrasound diagnostic performance improvement when utilizing maternal-fetal medicine interpretation. Am J Obstet Gynecol 2021. [DOI: 10.1016/j.ajog.2020.12.648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
21
|
Roman A, Zork N, Haeri S, Schoen CN, Saccone G, Colihan S, Zelig C, Gimovsky AC, Seligman NS, Zullo F, Berghella V. Physical examination-indicated cerclage in twin pregnancy: a randomized controlled trial. Am J Obstet Gynecol 2020; 223:902.e1-902.e11. [PMID: 32592693 DOI: 10.1016/j.ajog.2020.06.047] [Citation(s) in RCA: 47] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2020] [Revised: 05/19/2020] [Accepted: 06/22/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Women with twin pregnancies and a dilated cervix in the second trimester are at increased risk of pregnancy loss and early preterm birth; there is currently no proven therapy to prevent preterm birth in this group of women. OBJECTIVE This study aimed to determine whether physical examination-indicated cerclage reduces the incidence of preterm birth in women with a diagnosis of twin pregnancies and asymptomatic cervical dilation before 24 weeks of gestation. STUDY DESIGN Multicenter, parallel group, open-label, randomized controlled trial of women with twin pregnancies and asymptomatic cervical dilation of 1 to 5 cm between 16 weeks 0/7 days of gestation and 23 weeks 6/7 days of gestation were enrolled from July 2015 to July 2019 in 8 centers. Eligible women were randomized in a 1:1 ratio into either cerclage or no cerclage groups. We excluded women with monochorionic-monoamniotic twin pregnancy, selective fetal growth restriction, twin-twin transfusion syndrome, major fetal malformation, known genetic anomaly, placenta previa, signs of labor, or clinical chorioamnionitis. The primary outcome was the incidence of preterm birth at <34 weeks of gestation. Secondary outcomes were preterm births at <32, <28, and <24 weeks of gestation, interval from diagnosis to delivery, and perinatal mortality. Data were analyzed by intention-to-treat methods. RESULTS After an interim analysis was performed, the Data and Safety Monitoring Board recommended stopping the trial because of a significant decrease in perinatal mortality in the cerclage group. We randomized 34 women, with 4 women being excluded because of expired informed consent. A total of 17 women were randomized to physical examination-indicated cerclage and 13 women to no cerclage. Whereas 4 women randomized to cerclage did not receive the surgical procedure, no women in the no cerclage group received cerclage. Maternal demographics were not significantly different. All women in the cerclage group also received indomethacin and antibiotics. When comparing the cerclage group vs the no cerclage group, the incidence of preterm birth was significantly decreased as follows: preterm birth at <34 weeks of gestation, 12 of 17 women (70%) vs 13 of 13 women (100%) (risk ratio, 0.71; 95% confidence interval, 0.52-0.96); preterm birth at <32 weeks of gestation, 11 of 17 women (64.7%) vs 13 of 13 women (100%) (risk ratio, 0.65; 95% confidence interval, 0.46-0.92); preterm birth at <28 weeks of gestation, 7 of 17 women (41%) vs 11 of 13 women (84%) (risk ratio, 0.49; 95% confidence interval, 0.26-0.89); and preterm birth at <24 weeks of gestation, 5 of 17 women (30%) vs 11 of 13 women (84%) (risk ratio, 0.35; 95% confidence interval, 0.16-0.75). The mean gestational age at delivery was 29.05±1.7 vs 22.5±3.9 weeks (P<.01), respectively; the mean interval from diagnosis of cervical dilation to delivery was 8.3±5.8 vs 2.9±3.0 weeks (P=.02), respectively. Perinatal mortality was also significantly reduced in the cerclage group compared with the no cerclage group as follows: 6 of 34 women (17.6%) vs 20 of 26 women (77%) (risk ratio, 0.22; 95% confidence interval, 0.1-0.5), respectively. CONCLUSION In women with twin pregnancies and asymptomatic cervical dilation before 24 weeks of gestation, a combination of physical examination-indicated cerclage, indomethacin, and antibiotics significantly decreased preterm birth at all evaluated gestational ages. Most importantly, cerclage in this population was associated with a 50% decrease in early preterm birth at <28 weeks of gestation and with a 78% decrease in perinatal mortality.
Collapse
Affiliation(s)
- Amanda Roman
- Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.
| | - Noelia Zork
- Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Columbia University, New York, NY
| | - Sina Haeri
- Division of Maternal-Fetal Medicine, Obstetrics and Gynecology Department, St David's Women's Center of Texas, Austin, TX
| | - Corina N Schoen
- Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Massachusetts Medical School-Baystate, Springfield, MA
| | - Gabriele Saccone
- Department of Neuroscience, Reproductive Sciences, and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy
| | - Sarah Colihan
- Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Albany Medical Center, Albany, NY
| | - Craig Zelig
- Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Albany Medical Center, Albany, NY
| | - Alexis C Gimovsky
- Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, the George Washington University School of Medicine and Health Sciences, Washington, DC
| | - Neil S Seligman
- Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, NY
| | - Fulvio Zullo
- Department of Neuroscience, Reproductive Sciences, and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy
| | - Vincenzo Berghella
- Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA
| |
Collapse
|
22
|
Haeri S, Benedetti L, Ghita O. Effects of particle elongation on the binary coalescence dynamics of powder grains for Laser Sintering applications. POWDER TECHNOL 2020. [DOI: 10.1016/j.powtec.2019.12.025] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
23
|
Ibirogba ER, Haeri S, Ruano R. Fetal lower urinary tract obstruction: What should we tell the prospective parents? Prenat Diagn 2020; 40:661-668. [PMID: 32065667 DOI: 10.1002/pd.5669] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2019] [Revised: 01/28/2020] [Accepted: 02/12/2020] [Indexed: 11/07/2022]
Abstract
Fetal lower urinary tract obstruction (LUTO), which often results in marked perinatal morbidity and mortality, is caused by a heterogeneous group of anatomical defects that lead to blockage of the urethra. The classic prenatal presentation of LUTO includes megacystis with hydronephrosis. While mild forms of the disease can be associated with favorable outcomes, more severe disease commonly leads to dysplastic changes in the fetal kidneys, and ultimately oligohydramnios, which can result in secondary pulmonary hypoplasia and renal failure at birth. The aim of this review is to provide practitioners with a general overview of the diagnosis and treatment of LUTO based on disease severity, along with some points to consider when counseling prospective parents of fetuses with this condition.
Collapse
Affiliation(s)
- Eniola Raheem Ibirogba
- Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, Rochester, Minnesota
| | - Sina Haeri
- St. David's Women's Center of Texas, Austin Maternal-Fetal Medicine, Austin, Texas
| | - Rodrigo Ruano
- Department of Obstetrics and Gynecology, Mayo Clinic College of Medicine, Rochester, Minnesota
| |
Collapse
|
24
|
Roman A, Zork N, Haeri S, Schoen CN, Saccone G, Colihan S, Gimovsky AC, Seligman NS, Zelig C, Martinelli P, Berghella V. 692: Physical exam indicated cerclage in twin pregnancy, randomized clinical trial. Am J Obstet Gynecol 2020. [DOI: 10.1016/j.ajog.2019.11.706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
25
|
Erfani H, Haeri S, Shainker SA, Saad AF, Ruano R, Dunn TN, Rezaei A, Aalipour S, Nassr AA, Shamshirsaz AA, Vaughn M, Lindsley W, Spiel MH, Shazly SA, Ibirogba ER, Clark SL, Saade GR, Belfort MA, Shamshirsaz AA. Vasa previa: a multicenter retrospective cohort study. Am J Obstet Gynecol 2019; 221:644.e1-644.e5. [PMID: 31201807 DOI: 10.1016/j.ajog.2019.06.006] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Revised: 05/15/2019] [Accepted: 06/05/2019] [Indexed: 10/26/2022]
Abstract
OBJECTIVE The objective of the study was to describe the characteristics and outcomes of patients with antenatal diagnosis of vasa previa and evaluate the predictive factors of resolution in a contemporary large, multicenter data set. STUDY DESIGN This was a retrospective multicenter cohort study of all antenatally diagnosed cases of vasa previa, identified via ultrasound and electronic medical record, between January 2011 and July 2018 in 5 US centers. Records were abstracted to obtain variables at diagnosis, throughout pregnancy, and outcomes, including maternal and neonatal variables. Data were reported as median [range] or n (percentage). Descriptive statistics, receiver-operating characteristics, and logistic regression analysis were used as appropriate. RESULTS One hundred thirty-six cases of vasa previa were identified in 5 centers during the study period, 19 (14%) of which resolved spontaneously at median estimated gestational age of 27 weeks [19-34]. All subjects with unresolved vasa previa underwent cesarean delivery at a median estimated gestational age of 34 weeks [27-39] with the median estimated blood loss of 800 mL [250-2000]. Rates for vaginal bleeding, preterm labor, premature rupture of membrane, and need for blood product transfusion were not different between the resolved and unresolved group (P = NS). The odds ratio for resolution in those with the estimated gestational age of less than 24 weeks at the time of diagnosis was 7.9 (95% confidence interval, 2.1-29.4) after adjustment for confounding variables. CONCLUSION Our data suggest that outcomes in antenatally diagnosed cases of vasa previa are excellent. Furthermore, our data report a higher chance of resolution when the condition is diagnosed before 24 weeks of gestation.
Collapse
|
26
|
|
27
|
Mansouri M, DeStefano K, Monks B, Singh J, McDonnold M, Morgan J, Hale R, Adusumalli J, Horton A, Haeri S. Treatment of Morbidly Adherent Placentation Utilizing a Standardized Multidisciplinary Approach in the Community Hospital-Private Practice Setting. AJP Rep 2017; 7:e211-e214. [PMID: 29177107 PMCID: PMC5699905 DOI: 10.1055/s-0037-1608641] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/12/2017] [Accepted: 09/26/2017] [Indexed: 11/24/2022] Open
Abstract
Objective Morbidly adherent placentation is associated with increased maternal morbidity and mortality. Recently, there has been mounting evidence supporting the benefits of a standardized multidisciplinary approach at tertiary teaching hospitals. Our objective was to estimate the impact of the implementation of a similar program at a high-volume private community hospital. Study Design In this retrospective cohort study, we evaluated maternal outcomes in all cases of histopathologically confirmed morbidly adherent placentation since the initiation of our multidisciplinary program (2012-2016). Our data were compared with the previously published outcomes of two large cohorts from tertiary teaching hospitals in Utah and Texas. Results In the 28 cases included for evaluation, our group's median estimated blood loss, median packed red blood cells transfused, median anesthesia time, median length of stay, or rates of maternal morbidity did not statistically differ from the published data in Utah or Texas. Conclusion Our data demonstrate the feasibility and utility of a multidisciplinary morbidly adherent placentation program in the private practice/community hospital setting with outcomes similar to those at tertiary teaching hospitals. Implementation of such program may prove beneficial in remote centers, where various factors may prohibit patient travel to a larger center.
Collapse
Affiliation(s)
| | - Kim DeStefano
- Austin Maternal-Fetal Medicine, Austin, Texas.,St. David's Women's Center of Texas, Austin, Texas
| | - Brian Monks
- St. David's Women's Center of Texas, Austin, Texas.,OB Hospitalist Group, Mauldin, South Carolina
| | - Jasbir Singh
- Austin Maternal-Fetal Medicine, Austin, Texas.,St. David's Women's Center of Texas, Austin, Texas
| | - Mollie McDonnold
- Austin Maternal-Fetal Medicine, Austin, Texas.,St. David's Women's Center of Texas, Austin, Texas
| | - Jamison Morgan
- St. David's Women's Center of Texas, Austin, Texas.,OB Hospitalist Group, Mauldin, South Carolina
| | - Richard Hale
- Austin Maternal-Fetal Medicine, Austin, Texas.,St. David's Women's Center of Texas, Austin, Texas
| | - Jasvant Adusumalli
- Austin Maternal-Fetal Medicine, Austin, Texas.,St. David's Women's Center of Texas, Austin, Texas
| | - Amanda Horton
- Austin Maternal-Fetal Medicine, Austin, Texas.,St. David's Women's Center of Texas, Austin, Texas
| | - Sina Haeri
- Austin Maternal-Fetal Medicine, Austin, Texas.,St. David's Women's Center of Texas, Austin, Texas
| |
Collapse
|
28
|
Johnston RC, Haeri S, Hale RT, Lindsley W, McCormick A, Su E. The Value of Implementing Multidisciplinary Perinatal Care Conference in the Private Practice Setting. AJP Rep 2017; 7:e201-e204. [PMID: 29142784 PMCID: PMC5683892 DOI: 10.1055/s-0037-1608640] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/13/2017] [Accepted: 09/26/2017] [Indexed: 12/03/2022] Open
Abstract
Objective The objective of this study was to estimate the impact of multidisciplinary (Multi-D) perinatal care conference (PCC) implementation in the private practice setting. Methods After the initial 12-month period following implementation of the monthly PCC by private maternal-fetal medicine and neonatology practitioners, conference attendees were asked to completed a modified version of the Attitudes Toward Health Care Teams Scale, involving 19 questions assessing their attitudes and opinions toward Multi-D team care on a five-point Likert's scale. Results Of the 51 average attendees to the PCC, 82.3% completed the survey. A majority of respondents agreed that Multi-D team care resulted in improved care for patients and family, was not overly complex to coordinate, and resulted in significant job satisfaction and improved medical knowledge. Conclusion Multi-D care is an effective approach to the complicated needs of maternal-fetal medicine patients which may lead to improved patient and family outcomes, high provider satisfaction, and can easily be implemented and utilized within a private practice or community hospital setting.
Collapse
Affiliation(s)
| | - Sina Haeri
- Austin Maternal-Fetal Medicine, Austin, Texas
- St. David's Women's Center of Texas, Austin, Texas
| | - Richard T. Hale
- Austin Maternal-Fetal Medicine, Austin, Texas
- St. David's Women's Center of Texas, Austin, Texas
| | - William Lindsley
- Austin Maternal-Fetal Medicine, Austin, Texas
- St. David's Women's Center of Texas, Austin, Texas
| | | | - Eric Su
- St. David's Women's Center of Texas, Austin, Texas
| |
Collapse
|
29
|
Song H, Haeri S, Vogel H, van der Knaap M, Van Haren K. Postmortem Whole Exome Sequencing Identifies Novel EIF2B3 Mutation With Prenatal Phenotype in 2 Siblings. J Child Neurol 2017; 32:867-870. [PMID: 28597716 DOI: 10.1177/0883073817712588] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
OBJECTIVE We describe 2 male siblings with a severe, prenatal phenotype of vanishing white matter disease and the impact of whole exome sequencing on their diagnosis and clinical care. METHODS The 2 children underwent detailed clinical characterization, through clinical and laboratory testing, as well as prenatal and postnatal imaging. Biobanked blood from the 2 siblings was submitted for whole exome sequencing at Baylor Laboratories. RESULTS Both male children had abnormal prenatal neuroimaging and suffered precipitous, fatal neurologic decline. Neuropathologic findings included subependymal pseudocysts, microcalcifications, and profound lack of brain myelin and sparing of peripheral nerve myelin. A novel homozygous mutation in the EIF2B3 gene (c.97A>G [p.Lys33Glu]) was found in both children; both parents were heterozygous carriers. The family subsequently conceived a healthy child via in vitro fertilization with preimplantation mutation screening. CONCLUSION These histories expand the prenatal phenotype of eIF2b-related disorders and poignantly illustrate the impact that unbiased genomic sequencing can have on the diagnosis and medical decision making for families affected by childhood neurodegenerative disorders.
Collapse
Affiliation(s)
| | - Sina Haeri
- 2 St. David's Women's Center of Texas, Austin-Maternal Fetal Medicine, Austin, TX, USA
| | - Hannes Vogel
- 3 Department of Pathology, Stanford University Medical Center, Stanford, CA, USA
| | - Marjo van der Knaap
- 4 Departments of Pediatrics and Child Neurology, VU University Medical Center, Amsterdam, the Netherlands
| | - Keith Van Haren
- 5 Department of Neurology, Stanford University Medical Center, Stanford, CA, USA
| |
Collapse
|
30
|
Haeri S, Simon DH, Pillutla K. Serial amnioinfusions for fetal pulmonary palliation in fetuses with renal failure. J Matern Fetal Neonatal Med 2016; 30:174-176. [DOI: 10.3109/14767058.2016.1165202] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
31
|
Affiliation(s)
| | - Sina Haeri
- St. David’s North Austin Medical Center Women’s Center of Texas, Austin Maternal–Fetal Medicine, Austin, TX, USA
| |
Collapse
|
32
|
Lide B, Lindsley W, Foster MJ, Hale R, Haeri S. Intrahepatic Persistent Right Umbilical Vein and Associated Outcomes: A Systematic Review of the Literature. J Ultrasound Med 2016; 35:1-5. [PMID: 26635256 DOI: 10.7863/ultra.15.01008] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/08/2015] [Accepted: 04/27/2015] [Indexed: 06/05/2023]
Abstract
The aim of this study was to provide a comprehensive review of the current data surrounding an intrahepatic persistent right umbilical vein in the fetus, including associated anomalies and outcomes, and to assist practitioners in counseling and management of affected pregnancies. We performed a MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and Northern Light database search for articles reporting outcomes on prenatally diagnosed cases of a persistent right umbilical vein. Each article was independently reviewed for eligibility by the investigators. Thereafter, the data were extracted and validated independently by 3 investigators. A total of 322 articles were retrieved, and 16 were included in this systematic review. The overall prevalence of an intrahepatic persistent right umbilical vein was found to be 212 per 166,548 (0.13%). Of the 240 cases of an intrahepatic persistent right umbilical vein identified, 183 (76.3%) were isolated. The remaining cases had a coexisting abnormality, including 19 (7.9%) cardiac, 9 (3.8%) central nervous system, 15 (6.3%) genitourinary, 3 (1.3%) genetic, and 17 (7%) placental/cord (predominantly a single umbilical artery). In summary, a persistent right umbilical vein is commonly an isolated finding but may be associated with a coexisting cardiac defect in 8% of cases. Therefore, consideration should be given to fetal echocardiography in cases of a persistent right umbilical vein.
Collapse
Affiliation(s)
- Brianna Lide
- Texas A&M Health Science Center College of Medicine, Temple, Texas USA (B.L.); St David's North Austin Medical Center Women's Center of Texas, Austin Maternal-Fetal Medicine, Austin, Texas USA (W.L., R.H., S.H.); and Texas A&M University, Medical Sciences Library, College Station, Texas USA (M.J.F.)
| | - William Lindsley
- Texas A&M Health Science Center College of Medicine, Temple, Texas USA (B.L.); St David's North Austin Medical Center Women's Center of Texas, Austin Maternal-Fetal Medicine, Austin, Texas USA (W.L., R.H., S.H.); and Texas A&M University, Medical Sciences Library, College Station, Texas USA (M.J.F.)
| | - Margaret J Foster
- Texas A&M Health Science Center College of Medicine, Temple, Texas USA (B.L.); St David's North Austin Medical Center Women's Center of Texas, Austin Maternal-Fetal Medicine, Austin, Texas USA (W.L., R.H., S.H.); and Texas A&M University, Medical Sciences Library, College Station, Texas USA (M.J.F.)
| | - Richard Hale
- Texas A&M Health Science Center College of Medicine, Temple, Texas USA (B.L.); St David's North Austin Medical Center Women's Center of Texas, Austin Maternal-Fetal Medicine, Austin, Texas USA (W.L., R.H., S.H.); and Texas A&M University, Medical Sciences Library, College Station, Texas USA (M.J.F.)
| | - Sina Haeri
- Texas A&M Health Science Center College of Medicine, Temple, Texas USA (B.L.); St David's North Austin Medical Center Women's Center of Texas, Austin Maternal-Fetal Medicine, Austin, Texas USA (W.L., R.H., S.H.); and Texas A&M University, Medical Sciences Library, College Station, Texas USA (M.J.F.).
| |
Collapse
|
33
|
Abstract
Fetal lower urinary tract obstruction (LUTO) is a serious condition, which commonly results in marked perinatal morbidity and mortality. The characteristic prenatal presentation of LUTO includes an enlarged bladder with bilateral obstructive uropathy. While mild forms of the disease result in minimal clinical sequelae, the more severe forms commonly lead to oligohydramnios, dysplastic changes in the fetal kidneys, and ultimately result in secondary pulmonary hypoplasia. The aim of this review is to provide practitioners with a practical and concise overview of the presentation, evaluation, and treatment of LUTO.
Collapse
Affiliation(s)
- Sina Haeri
- St. David's Women's Center of Texas, Austin Maternal-Fetal Medicine, 12200 Renfert Way, G-3, Austin, Austin, TX 78758 USA
| |
Collapse
|
34
|
Abstract
AIM The aim of this study was to estimate the impact of diabetes and obesity on cerebral autoregulation in pregnancy. METHODS Cerebral autoregulation was evaluated in women with gestational diabetes, type 2 diabetes mellitus and/or overweight (body mass index ⩾ 25 kg m(-2)) and compared to a cohort of euglycaemic pregnant women. The autoregulation index was calculated using simultaneously recorded cerebral blood flow velocity in the middle cerebral artery and blood pressure. Autoregulation index values of 0 and 9 indicate absent and perfect autoregulation, respectively. RESULTS Autoregulation index in women with either diabetes (n = 33, 6.6 ± 1.1) or overweight (n = 21, 6.7 ± 0.6) was not significantly different to that in control patients (n = 23, 6.6 ± 0.8, p = 0.96). CONCLUSION Cerebral autoregulation is not impaired in pregnant women who have non-vasculopathic diabetes or overweight. This suggests that the increased risk of pre-eclampsia in diabetic and overweight women is not associated with early impaired cerebral autoregulation.
Collapse
Affiliation(s)
- Teelkien R van Veen
- Department of Obstetrics and Gynaecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, USA
| | - Ronney B Panerai
- Department of Cardiovascular Sciences, University of Leicester, Leicester, UK NIHR Biomedical Research Unit in Cardiovascular Sciences, Glenfield Hospital, Leicester, UK
| | - Sina Haeri
- Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, USA St. David's Women's Center of Texas, North Austin Maternal-Fetal Medicine, Austin, TX, USA
| | - Paul P van den Berg
- Department of Obstetrics and Gynaecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Gerda G Zeeman
- Department of Obstetrics and Gynaecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
| | - Michael A Belfort
- Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, USA
| |
Collapse
|
35
|
Lindsley W, Hale R, Spear A, Adusumalli J, Singh J, DeStefano K, Haeri S. Does corticosteroid therapy impact fetal pulmonary artery blood flow in women at risk for preterm birth? Med Ultrason 2015; 17:280-283. [PMID: 26343073 DOI: 10.11152/mu.2013.2066.173.wly] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/05/2023]
Abstract
AIM Maternal corticosteroid administration in pregnancy is known to enhance fetal lung maturity in at risk fetuses. The aim of this study was to test the hypothesis that corticosteroid therapy alters fetal pulmonary blood flow in pregnancies at risk for preterm birth (PTB). MATERIAL AND METHODS We prospectively evaluated main fetal pulmonary artery (MPA) blood flow in pregnant women at risk for PTB and treated with corticosteroids (betamethasone), compared to an uncomplicated cohort without steroid therapy. The Doppler indices of interest included Peak Systolic Velocity (PSV), Resistive Index (RI), Pulsatility Index (PI), Systolic/Diastolic ratio (S/D ratio), Acceleration Time (AT), and Acceleration Time/Ejection Time Ratio (AT/ET ratio), with the latter serving as the primary outcomes due to its stability irrespective of gestational age. RESULTS When compared with controls, fetuses treated with corticosteroids demonstrated significantly decreased pulmonary artery acceleration time (median: 28.89 (22.22-51.11) vs. 33.33 (22.20-57.00), p=0.006), while all other indices remained similar. We found no difference in pulmonary blood flow between fetuses who developed respiratory distress syndrome (RDS) and those that did not (31.56 +/- 6.842 vs. 32.36 +/- 7.265, p= 0.76). CONCLUSION Our data demonstrate altered fetal pulmonary blood flow with corticosteroid therapy, possibly due to increased arterial elastance brought on by medication effect, which leads to the decreased acceleration time or possible gestational age affect. Contrary to a recent report, we did not observe any Doppler differences in fetuses with RDS, which underscores the need for further examination of this proposed association.
Collapse
Affiliation(s)
- William Lindsley
- St. David's North Austin Medical Center, Women's Center of Texas, Austin Maternal-Fetal Medicine, Austin, Texas, United States
| | - Richard Hale
- St. David's North Austin Medical Center, Women's Center of Texas, Austin Maternal-Fetal Medicine, Austin, Texas, United States
| | - Ashley Spear
- St. David's North Austin Medical Center, Women's Center of Texas, Austin Maternal-Fetal Medicine, Austin, Texas, United States
| | - Jasvant Adusumalli
- St. David's North Austin Medical Center, Women's Center of Texas, Austin Maternal-Fetal Medicine, Austin, Texas, United States
| | - Jasbir Singh
- St. David's North Austin Medical Center, Women's Center of Texas, Austin Maternal-Fetal Medicine, Austin, Texas, United States
| | - Kimberly DeStefano
- St. David's North Austin Medical Center, Women's Center of Texas, Austin Maternal-Fetal Medicine, Austin, Texas, United States
| | - Sina Haeri
- St. David's North Austin Medical Center, Women's Center of Texas, Austin Maternal-Fetal Medicine, Austin, Texas, United States.
| |
Collapse
|
36
|
Ezzati M, Shamshirsaz AA, Haeri S. Undiagnosed heterotopic pregnancy, maternal hemorrhagic shock, and ischemic stroke in the intrauterine fetus. Prenat Diagn 2015; 35:926-7. [DOI: 10.1002/pd.4633] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2015] [Accepted: 06/04/2015] [Indexed: 11/06/2022]
Affiliation(s)
- Mohammad Ezzati
- Department of Obstetrics and Gynecology; University of Texas Southwestern Medical Center; Dallas TX USA
| | | | - Sina Haeri
- St. David's Women's Center of Texas; Austin Maternal-Fetal Medicine; Austin TX USA
| |
Collapse
|
37
|
van Veen TR, Panerai RB, Haeri S, Singh J, Adusumalli JA, Zeeman GG, Belfort MA. Cerebral autoregulation in different hypertensive disorders of pregnancy. Am J Obstet Gynecol 2015; 212:513.e1-7. [PMID: 25446701 DOI: 10.1016/j.ajog.2014.11.003] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2014] [Revised: 10/12/2014] [Accepted: 11/01/2014] [Indexed: 11/24/2022]
Abstract
OBJECTIVE Cerebrovascular complications that are associated with hypertensive disorders of pregnancy (preeclampsia, chronic hypertension [CHTN], and gestational hypertension [GHTN]) are believed to be associated with impaired cerebral autoregulation, which is a physiologic process that maintains blood flow at an appropriate level despite changes in blood pressure. The nature of autoregulation dysfunction in these conditions is unclear. We therefore evaluated autoregulation in 30 patients with preeclampsia, 30 patients with CHTN, and 20 patients with GHTN and compared them with a control group of 30 normal pregnant women. STUDY DESIGN The autoregulatory index (ARI) was calculated with the use of simultaneously recorded cerebral blood flow velocity in the middle cerebral artery (transcranial Doppler ultrasound), blood pressure (noninvasive arterial volume clamping), and end-tidal carbon dioxide during a 7-minute period of rest. ARI values of 0 and 9 indicate absent and perfect autoregulation, respectively. We use analysis of variance with Bonferroni test vs a control group. Data are presented as mean ± standard deviation. RESULTS ARI was significantly reduced in preeclampsia (ARI, 5.5 ± 1.6; P = .002) and CHTN (ARI, 5.6 ± 1.7; P = .004), but not in GHTN (ARI, 6.7 ± 0.8; P = 1.0) when compared with control subjects (ARI, 6.7 ± 0.8). ARI was more decreased in patients with CHTN who subsequently experienced preeclampsia than in those who did not (ARI, 3.9 ± 1.9 vs 6.1 ± 1.2; P = .001). This was not true for women with GHTN or control subjects who later experienced preeclampsia. CONCLUSION Pregnant women with CHTN or preeclampsia (even after exclusion of superimposed preeclampsia) have impaired autoregulation when compared with women with GHTN or normal pregnancy. Whether the decreased ARI in patients with CHTN who later experience preeclampsia is due to preexistent differences or early affected cerebral circulation remains to be determined.
Collapse
|
38
|
Abstract
Purpose Postural orthostatic tachycardia syndrome (POTS) is a form of orthostatic intolerance characterized by an increased heart rate upon transition from supine to standing, and head-up tilt without orthostatic hypotension. Its etiology is multifactorial, and no clear cause has been identified. Common symptoms include light-headedness, blurred vision, weakness, cognitive difficulties, and fatigue and are often accompanied by palpitations, shortness of breath, syncope, or gastrointestinal symptoms. Management includes volume expansion, physical counter maneuvers, and pharmacological agents such as fludrocortisone, midodrine, propranolol, and pyridostigmine. The course of POTS in pregnancy is variable and POTS has not been directly implicated in any adverse outcomes for the mother or fetus. Methods Two cases of POTS in pregnancy are presented, along with a review of the literature for reports of POTS in pregnancy. Results Along with our 2 cases, 10 other case reports were identified and included. Conclusion The course of POTS in pregnancy is variable, and not directly linked to increase perinatal morbidity or mortality. Women can safely undergo regional anesthesia, and vaginal delivery with close monitoring of hemodynamic changes.
Collapse
Affiliation(s)
- Brianna Lide
- Texas A and M University College of Medicine, Temple, Texas
| | - Sina Haeri
- St. David's North Austin Medical Center, Austin, Texas ; Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, Texas
| |
Collapse
|
39
|
Shamshirsaz AA, Javadian P, Ruano R, Haeri S, Sangi-Haghpeykar H, Lee TC, Molohon J, Cass DL, Salmanian B, Mollett L, Moaddab A, Espinosa J, Olutoye OO, Belfort MA. Comparison between laparoscopically assisted and standard fetoscopic laser ablation in patients with anterior and posterior placentation in twin-twin transfusion syndrome: a single center study. Prenat Diagn 2015; 35:376-81. [PMID: 25559783 DOI: 10.1002/pd.4552] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2014] [Revised: 11/18/2014] [Accepted: 12/24/2014] [Indexed: 11/07/2022]
Abstract
BACKGROUND The objective of our study was to compare outcomes following laparoscopically assisted procedure (LAP group) with those seen following a standard approach used in patients with either an anterior placenta (SAP group) or posterior placenta (SPP group). METHOD This was a retrospective review of all the cases of twin-twin transfusion syndrome treated in our fetal center from October 2011 to July 2013. Technical characteristics of the procedure, perinatal survival outcome, and maternal morbidity were compared. RESULTS The laser procedure time was significantly longer in the SAP group (44 ± 10 min) in contrast with SPP (19.3 ± 13.9 min, p < 0.001) and LAP group (32 ± 11 min, p: 0.012). Preterm premature rupture of membranes (PPROM) before 32 and 34 weeks of pregnancy was significantly more common with LAP versus SAP and SPP (90 vs 33.3 and 70.8% for 32 weeks respectively, p: 0.015; 100 vs 50 and 79.1% for 34 weeks respectively, p: 0.021). In terms of maternal morbidity and neonatal outcome, there were no significant differences between the three groups. CONCLUSION LAP may be useful in cases where SAP is not feasible. Despite the increased risk of PPROM with LAP, perinatal survival and maternal outcomes are similar to that seen in SAP and SPP patients.
Collapse
Affiliation(s)
- Alireza A Shamshirsaz
- Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Araujo Júnior E, Rolo LC, Tonni G, Haeri S, Ruano R. Assessment of fetal malformations in the first trimester of pregnancy by three-dimensional ultrasonography in the rendering mode. Pictorial essay. Med Ultrason 2015; 17:109-114. [PMID: 25745664 DOI: 10.11152/mu.2013.2066.171.eaj] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
We present our experience in the contribution of three-dimensional ultrasonography, using the rendering mode, to the prenatal diagnosis of congenital anomalies including neurological defects (acrania/anencephaly, encephalocele, holoprosencephaly), facial anomalies (cyclopia and facial clefts), abdominal wall defects (omphalocele and gastroschisis) and defects of extremities (fetal muscle-skeletal dysplasias). Three-dimensional ultrasonography may contribute to improve the prenatal diagnosis with further revision of the fetal images, allowing a better prenatal counsel to the parents.
Collapse
Affiliation(s)
- Edward Araujo Júnior
- Department of Obstetrics, Paulista School of Medicine - São Paulo Federal University (EPM-UNIFESP), São Paulo, Brazil. E-mail:
| | - Liliam Cristine Rolo
- Department of Obstetrics, Paulista School of Medicine - São Paulo Federal University (EPM-UNIFESP), São Paulo, Brazil
| | - Gabriele Tonni
- Department of Obstetrics and Gynecology, Prenatal Diagnostic Center, Guastalla Civil Hospital, Reggio Emilia, Italy
| | - Sina Haeri
- Department of Obstetrics & Gynecology, Division of Maternal-Fetal Medicine, Baylor College of Medicine & Texas Children's Hospital, Houston, TX, USA
| | - Rodrigo Ruano
- Department of Obstetrics & Gynecology, Division of Maternal-Fetal Medicine, Baylor College of Medicine & Texas Children's Hospital, Houston, TX, USA
| |
Collapse
|
41
|
Lindsley W, Haeri S. Placental Mesenchymal Dysplasia (PMD) in Association With Beckwith-Wiedemann Syndrome Identified by First Trimester Sonography. Journal of Diagnostic Medical Sonography 2015. [DOI: 10.1177/8756479315570738] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Placental mesenchymal dysplasia (PMD) has commonly been identified on second trimester ultrasound in association with Beckwith-Wiedemann syndrome (BWS). In this report, a case of PMD later confirmed as Beckwith-Wiedemann is presented, which was identified by sonography in the first trimester. When faced with a first trimester finding of an enlarged cystic placenta, it is suggested that BWS be considered as a possible diagnosis and accordingly, genetic testing with methylation studies offered to the parents.
Collapse
Affiliation(s)
| | - Sina Haeri
- Austin Maternal Fetal Medicine, Austin, TX, USA
- Baylor College of Medicine, Department of Obstetrics & Gynecology, Houston, Texas, USA
| |
Collapse
|
42
|
van Veen TR, Haeri S. Gout in Pregnancy: A Case Report and Review of the Literature. Gynecol Obstet Invest 2015; 79:217-21. [DOI: 10.1159/000369999] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2014] [Accepted: 11/18/2014] [Indexed: 11/19/2022]
|
43
|
van Veen TR, Panerai RB, Haeri S, Zeeman GG, Belfort MA. Effect of breath holding on cerebrovascular hemodynamics in normal pregnancy and preeclampsia. J Appl Physiol (1985) 2015; 118:858-62. [PMID: 25614597 DOI: 10.1152/japplphysiol.00562.2014] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2014] [Accepted: 01/20/2015] [Indexed: 11/22/2022] Open
Abstract
Preeclampsia (PE) is associated with endothelial dysfunction and impaired autonomic function, which is hypothesized to cause cerebral hemodynamic abnormalities. Our aim was to test this hypothesis by estimating the difference in the cerebrovascular response to breath holding (BH; known to cause sympathetic stimulation) between women with preeclampsia and a group of normotensive controls. In a prospective cohort analysis, cerebral blood flow velocity (CBFV) in the middle cerebral artery (transcranial Doppler), blood pressure (BP, noninvasive arterial volume clamping), and end-tidal carbon dioxide (EtCO2) were simultaneously recorded during a 20-s breath hold maneuver. CBFV changes were broken down into standardized subcomponents describing the relative contributions of BP, cerebrovascular resistance index (CVRi), critical closing pressure (CrCP), and resistance area product (RAP). The area under the curve (AUC) was calculated for changes in relation to baseline values. A total of 25 preeclamptic (before treatment) and 25 normotensive women in the second half of pregnancy were enrolled, and, 21 patients in each group were included in the analysis. The increase in CBFV and EtCO2 was similar in both groups. However, the AUC for CVRi and RAP during BH was significantly different between the groups (3.05 ± 2.97 vs. -0.82 ± 4.98, P = 0.006 and 2.01 ± 4.49 vs. -2.02 ± 7.20, P = 0.037), indicating an early, transient increase in CVRi and RAP in the control group, which was absent in PE. BP had an equal contribution in both groups. Women with preeclampsia have an altered initial CVRi response to the BH maneuver. We propose that this is due to blunted sympathetic or myogenic cerebrovascular response in women with preeclampsia.
Collapse
Affiliation(s)
- Teelkien R van Veen
- University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, Groningen, the Netherlands; Baylor College of Medicine, Department of Obstetrics and Gynecology, Houston, Texas;
| | - Ronney B Panerai
- University of Leicester, Department of Cardiovascular Sciences, Leicester, United Kingdom; and
| | - Sina Haeri
- Baylor College of Medicine, Department of Obstetrics and Gynecology, Houston, Texas; St. David's Women's Center of Texas, North Austin Maternal-Fetal Medicine, Austin, Texas
| | - Gerda G Zeeman
- University of Groningen, University Medical Center Groningen, Department of Obstetrics and Gynecology, Groningen, the Netherlands
| | - Michael A Belfort
- Baylor College of Medicine, Department of Obstetrics and Gynecology, Houston, Texas
| |
Collapse
|
44
|
Abstract
Uterine inversion is a rare but life-threatening obstetrical emergency that occurs when the fundus of the uterus prolapses through the cervix, hence turning the uterus inside out. In this case report, we present our experience using an intrauterine tamponade balloon for management of uterine inversion, and a review of the literature. The utility of an intrauterine tamponade balloon in cases of uterine inversion, especially when maternal medical conditions preclude the use of uterotonics, or reinversion is observed should be kept in mind.
Collapse
Affiliation(s)
- Sina Haeri
- North Austin Maternal-Fetal Medicine, Austin, Texas, USA Department of Obstetrics & Gynecology, Baylor College of Medicine, Houston, Texas, USA
| | - Sheliza Rais
- Women's Center of Texas, St. David's North Austin Medical Center, Austin, Texas, USA
| | - Brian Monks
- OB Hospitalist Group, Mauldin, South Carolina, USA
| |
Collapse
|
45
|
Abstract
Isaacs' syndrome is a rare neuromuscular disorder of continuous muscle fibre activity resulting from peripheral nerve hyperexcitability. Symptoms commonly include myokymia (muscle twitching at rest), pseudomyotonia (delayed muscle relaxation), muscle cramps and stiffness. It is caused by voltage-gated potassium channel dysfunction and may be inherited or acquired. Treatment commonly includes anticonvulsants, immunosuppressive therapy and plasma exchange. To date only two cases of Isaacs' syndrome in pregnancy have been reported. We present a case of maternal Isaacs' along with a review of the literature. There are few reports of Isaacs' syndrome in pregnancy, but all are associated with favourable outcomes. Given the autosomal dominant inheritance pattern, genetic counselling of the gravida is recommended. Anticonvulsant may have to be used in pregnancy, and given the potential teratogenicity with several of these agents; preference should be given to newer drugs such as lamotrigine.
Collapse
Affiliation(s)
- Brianna Lide
- Texas A&M University College of Medicine, Bryan, Texas, USA
| | - Jasbir Singh
- North Austin Maternal-Fetal Medicine, Austin, Texas, USA
| | - Sina Haeri
- Department of Obstetrics & Gynecology, Baylor College of Medicine, Houston, Texas, USA
| |
Collapse
|
46
|
Postma IR, van Veen TR, Mears SL, Zeeman GG, Haeri S, Belfort MA. The effect of neuraxial anesthesia on maternal cerebral hemodynamics. Am J Perinatol 2014; 31:787-93. [PMID: 24338117 DOI: 10.1055/s-0033-1359715] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
OBJECTIVE Neuraxial anesthesia is known to reduce sympathetic tone and mean arterial pressure. Effects on cerebral hemodynamics in pregnancy are not well known. We hypothesize that cerebral hemodynamic parameters will change with respect to baseline following regional analgesia/anesthesia. STUDY DESIGN We performed maternal transcranial Doppler of the middle cerebral artery in 20 women receiving epidural analgesia for labor, and 18 undergoing spinal anesthesia for cesarean section at baseline, 5 and 15 minutes. Systemic blood pressure (BP), systolic/diastolic/mean velocity, resistance and pulsatility index (PI) were recorded. Cerebral perfusion pressure, critical closing pressure (CrCP), resistance area product, and cerebral flow index were calculated. RESULTS Epidural placement was associated with significant decreases in systolic/diastolic BP/mean velocity/CrCP after 15 minutes, with a corresponding increase in PI. In the spinal group, systolic/diastolic BP/mean velocity uniformly decreased and remained low after 15 minutes, and PI significantly increased and remained constant after 15 minutes. No differences were seen in BP or cerebral hemodynamics between the groups. CONCLUSION This study demonstrates that both epidural analgesia and spinal anesthesia result in measurable cerebral hemodynamic changes in normotensive term pregnancy that are likely to be clinically insignificant as they do not affect perfusion pressure or flow.
Collapse
Affiliation(s)
- Ineke R Postma
- Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - Teelkien R van Veen
- Department of Obstetrics and Gynecology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - Scott L Mears
- Department of Anesthesiology, St Mark's Hospital, Salt Lake City, Utah
| | - Gerda G Zeeman
- Division of Obstetrics and Prenatal Medicine, Department of Obstetrics and Gynecology, Erasmus Medical Center, Rotterdam, The Netherlands
| | - Sina Haeri
- Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas
| | - Michael A Belfort
- Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas
| |
Collapse
|
47
|
Allaf MB, Campbell WA, Vintzileos AM, Haeri S, Javadian P, Shamshirsaz AA, Ogburn P, Figueroa R, Wax J, Markenson G, Chavez MR, Ravangard SF, Ruano R, Sangi-Haghpeykar H, Salmanian B, Meyer M, Johnson J, Ozhand A, Davis S, Borgida A, Belfort MA, Shamshirsaz AA. Does early second-trimester sonography predict adverse perinatal outcomes in monochorionic diamniotic twin pregnancies? J Ultrasound Med 2014; 33:1573-1578. [PMID: 25154937 DOI: 10.7863/ultra.33.9.1573] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
OBJECTIVES To determine whether intertwin discordant abdominal circumference, femur length, head circumference, and estimated fetal weight sonographic measurements in early second-trimester monochorionic diamniotic twins predict adverse obstetric and neonatal outcomes. METHODS We conducted a multicenter retrospective cohort study involving 9 regional perinatal centers in the United States. We examined the records of all monochorionic diamniotic twin pregnancies with two live fetuses at the 16- to 18-week sonographic examination who had serial follow-up sonography until delivery. The intertwin discordance in abdominal circumference, femur length, head circumference, and estimated fetal weight was calculated as the difference between the two fetuses, expressed as a percentage of the larger using the 16- to 18-week sonographic measurements. An adverse composite obstetric outcome was defined as the occurrence of 1 or more of the following in either fetus: intrauterine growth restriction, twin-twin transfusion syndrome, intrauterine fetal death, abnormal growth discordance (≥20% difference), and very preterm birth at or before 28 weeks. An adverse composite neonatal outcome was defined as the occurrence of 1 or more of the following: respiratory distress syndrome, any stage of intraventricular hemorrhage, 5-minute Apgar score less than 7, necrotizing enterocolitis, culture-proven early-onset sepsis, and neonatal death. Receiver operating characteristic and logistic regression-with-generalized estimating equation analyses were constructed. RESULTS Among the 177 monochorionic diamniotic twin pregnancies analyzed, intertwin abdominal circumference and estimated fetal weight discordances were only predictive of adverse composite obstetric outcomes (areas under the curve, 79% and 80%, respectively). Receiver operating characteristic curves showed that intertwin discordances in abdominal circumference, femur length, head circumference, and estimated fetal weight were not acceptable predictors of twin-twin transfusion syndrome or adverse neonatal outcomes. CONCLUSIONS In our cohort, only second-trimester abdominal circumference and estimated fetal weight discordances in monochorionic diamniotic twin pregnancies were predictive of adverse composite obstetric outcomes. Twin-twin transfusion syndrome and adverse neonatal outcomes were not predicted by any of the intertwin discordances measured.
Collapse
Affiliation(s)
- M Baraa Allaf
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Winston A Campbell
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Anthony M Vintzileos
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Sina Haeri
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Pouya Javadian
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Amir A Shamshirsaz
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Paul Ogburn
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Reinaldo Figueroa
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Joseph Wax
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Glenn Markenson
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Martin R Chavez
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Samadh F Ravangard
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Rodrigo Ruano
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Haleh Sangi-Haghpeykar
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Bahram Salmanian
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Marjorie Meyer
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Jeffery Johnson
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Ali Ozhand
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Sarah Davis
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Adam Borgida
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Michael A Belfort
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.)
| | - Alireza A Shamshirsaz
- Department of Obstetrics and Gynecology, Stony Brook Medicine, Stony Brook, New York USA (M.B.A., P.O., R.F.); Department of Obstetrics and Gynecology, Winthrop University Hospital, Mineola, New York USA (M.B.A., A.M.V., M.R.C.); Department of Obstetrics and Gynecology, University of Connecticut, Farmington, Connecticut USA (W.A.C., S.F.R., Al.A.S.); Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Hospital, Houston, Texas USA (S.H., P.J., R.R., H.S.-H., B.S., M.A.B., Al.A.S.); Department of Obstetrics and Gynecology, George Washington University, Washington, DC USA (Am.A.S.); Sidra Medical and Research Center, Doha, Qatar (P.O.); Hartford Hospital, Hartford, Connecticut USA (R.F., A.B.); Department of Obstetrics and Gynecology, Maine Medical Center, Portland, Maine USA (J.W., G.M.); Department of Obstetrics and Gynecology, Baystate Medical Center, Springfield, Massachusetts USA (S.F.R.); Department of Obstetrics and Gynecology, University of Illinois, Chicago, Illinois, USA (S.F.R.); Department of Obstetrics and Gynecology, University of Vermont, Burlington, Vermont USA (M.M., S.D.); Department of Obstetrics and Gynecology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire USA (J.J.); and Department of Preventive Medicine, University of Southern California, Los Angeles, California USA (A.O.).
| |
Collapse
|
48
|
Ruano R, Lazar DA, Cass DL, Zamora IJ, Lee TC, Cassady CI, Mehollin-Ray A, Welty S, Fernandes CJ, Haeri S, Belfort MA, Olutoye OO. Fetal lung volume and quantification of liver herniation by magnetic resonance imaging in isolated congenital diaphragmatic hernia. Ultrasound Obstet Gynecol 2014; 43:662-669. [PMID: 24127326 DOI: 10.1002/uog.13223] [Citation(s) in RCA: 74] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/02/2013] [Revised: 08/20/2013] [Accepted: 10/01/2013] [Indexed: 06/02/2023]
Abstract
OBJECTIVE To determine associations between fetal lung and liver herniation volumes measured by magnetic resonance imaging (MRI) and mortality/need for extracorporeal membrane oxygenation (ECMO) in cases of isolated congenital diaphragmatic hernia (CDH). A secondary objective was to compare prenatal MRI parameters with two-dimensional ultrasound lung measurements. METHODS A retrospective review of medical records of all fetuses with isolated CDH evaluated between January 2004 and July 2012 was performed. The following MRI parameters were measured at 20-32 weeks: observed/expected total fetal lung volume (o/e-TLV), predicted pulmonary volume (PPV), percentage of liver herniated into the fetal thorax (%LH) and the liver/thoracic volume ratio (LiTR). These were compared with the ultrasound-determined lung-to-head ratio (LHR) and the observed/expected LHR (o/e-LHR) in the same cohort. The predictive value of MRI and ultrasound parameters for mortality and the need for ECMO was evaluated by univariate, multivariate and factor analysis and by receiver-operating characteristics curves. RESULTS Eighty fetuses with isolated CDH were evaluated. Overall mortality was 18/80 (22.5%). Two newborns died a few hours after birth. ECMO was performed in 29/78 (37.2%) newborns, with a survival rate of 48.3% (14/29). The side of the diaphragmatic defect was not associated with mortality (P = 0.99) or the need for ECMO (P = 0.48). Good correlation was observed among o/e-TLV, PPV, LHR and o/e-LHR as well as between %LH and LiTR (r = 0.89; P < 0.01); however, fetal lung measurements and measures of liver herniation were not correlated (all P > 0.05). All parameters were statistically associated with mortality or the need for ECMO. The best combination of measurements to predict mortality was o/e-TLV and %LH, with 83% accuracy. CONCLUSION Mortality and the need for ECMO in neonates with isolated CDH can be best predicted using a combination of MRI o/e-TLV and %LH.
Collapse
Affiliation(s)
- R Ruano
- Texas Children's Fetal Center, Texas Children's Hospital, Houston, TX, USA; Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Shamshirsaz AA, Ravangard SF, Ozhand A, Haeri S, Shamshirsaz AA, Hussain N, Spiel M, Ogunleye O, Billstrom R, Sadowski A, Turner G, Timms D, Egan JFX, Campbell WA. Short-term neonatal outcomes in diamniotic twin pregnancies delivered after 32 weeks and indications of late preterm deliveries. Am J Perinatol 2014; 31:365-72. [PMID: 24166683 DOI: 10.1055/s-0033-1334458] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
OBJECTIVE We sought to compare neonatal outcomes in twin pregnancies following moderately preterm birth (MPTB), late preterm birth (LPTB), and term birth and determine the indications of LPTB. STUDY DESIGN We performed a retrospective cohort study. MPTB was defined as delivery between 32(0/7) and 33(6/7) weeks and LPTB between 34(0/7) and 36(6/7) weeks. The composite neonatal adverse respiratory outcome was defined as respiratory distress syndrome and/or bronchopulmonary dysplasia. The composite neonatal adverse nonrespiratory outcome included early onset culture-proven sepsis, necrotizing enterocolitis, retinopathy of prematurity, intraventricular hemorrhage, or periventricular leukomalacia. LPTB cases were categorized as spontaneous (noniatrogenic), evidence-based iatrogenic, and non-evidence-based (NEB) iatrogenic. RESULTS Of the 747 twin deliveries during the study period, 453 sets met the inclusion criteria with 22.7% (n = 145) MPTB, 32.1% (n = 206) LPTB, and 15.9% (n = 102) term births. Compared with term neonates, the composite neonatal adverse respiratory outcome was increased following MPTB (relative risk [RR] 24; 95% confidence interval [CI] 3.0 to 193.6) and LPTB (RR 13.7; 95% CI 1.8 to 101.8). Compared with term neonates, the composite neonatal adverse nonrespiratory outcome was increased following MPTB (RR 22.3; 95% CI 3.9 to 127.8) and LPTB (RR 5.5; 95% CI 1.1 to 27.6). Spontaneous delivery of LPTB was 63.6% (n = 131/206) and the rate of iatrogenic delivery was 36.4% (n = 75/206). The majority, 66.6% (n = 50/75), of these iatrogenic deliveries were deemed NEB, giving a total of 24.2% (50/206) NEB deliveries in LPTB group. CONCLUSION Our data demonstrate a high rate of late preterm birth among twin pregnancies, with over half of nonspontaneous early deliveries due to NEB indications. Although our morbidity data will be helpful to providers in counseling patients, our finding of high NEB indications underscores the need for systematic evaluation of indications for delivery in LPTB twin deliveries. Furthermore, this may lead to more effective LPTB rate reduction efforts.
Collapse
Affiliation(s)
- Alireza A Shamshirsaz
- Department of Obstetrics and Gynecology, Baylor College of Medicine/Texas Children's Hospital, Houston, Texas
| | - Samadh F Ravangard
- Department of Obstetrics and Gynecology, University of Connecticut Health Center, Farmington, Connecticut
| | - Ali Ozhand
- Department of Preventive Medicine, USC Keck School of Medicine, Los Angeles, California
| | - Sina Haeri
- Department of Obstetrics and Gynecology, Baylor College of Medicine/Texas Children's Hospital, Houston, Texas
| | - Amirhoushang A Shamshirsaz
- Department of Obstetrics and Gynecology, The George Washington University School of Medicine, Washington, District of Columbia
| | - Naveed Hussain
- Department of Pediatrics, University of Connecticut Health Center, Farmington, Connecticut
| | - Melissa Spiel
- Department of Obstetrics and Gynecology, University of Connecticut Health Center, Farmington, Connecticut
| | - Oluseyi Ogunleye
- Department of Obstetrics and Gynecology, Waverly Women's Health Care, Columbia, South Carolina
| | - Rachel Billstrom
- Department of Obstetrics and Gynecology, University of Connecticut Health Center, Farmington, Connecticut
| | - Alison Sadowski
- Department of Obstetrics and Gynecology, University of Connecticut Health Center, Farmington, Connecticut
| | - Garry Turner
- Department of Obstetrics and Gynecology, University of Connecticut Health Center, Farmington, Connecticut
| | - Diane Timms
- Department of Obstetrics and Gynecology, University of Connecticut Health Center, Farmington, Connecticut
| | - James F X Egan
- Department of Obstetrics and Gynecology, University of Connecticut Health Center, Farmington, Connecticut
| | - Winston A Campbell
- Department of Obstetrics and Gynecology, University of Connecticut Health Center, Farmington, Connecticut
| |
Collapse
|
50
|
Ruano R, Rodo C, Peiro JL, Shamshirsaz AA, Haeri S, Nomura ML, Salustiano EMA, De Andrade KK, Sangi-Haghpeykar H, Carreras E, Belfort MA. Reply: To PMID 23616360. Ultrasound Obstet Gynecol 2014; 43:239-240. [PMID: 24497424 DOI: 10.1002/uog.13281] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Affiliation(s)
- R Ruano
- Baylor College of Medicine and Texas Children's Hospital, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, Houston, TX, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|